Melanotan I (NDP-MSH) attenuates brain injury, oxidative stress, and apoptosis in mice after intracerebral hemorrhage via the PI3K/Akt/Nrf2 pathway.
Background
Secondary brain injury (SBI) following an intracerebral hemorrhage (ICH) is a major driver of poor outcomes, largely due to oxidative stress and neuronal apoptosis. Current treatments are limited in their ability to mitigate this complex cascade of damage. The melanocortin system, particularly the melanocortin-1 receptor (Mc1r), has emerged as a promising therapeutic target due to its anti-inflammatory properties. Nle4-D-Phe7-α-melanocyte-stimulating hormone (NDP-MSH), a potent synthetic Mc1r agonist, has shown neuroprotective effects in other disease models. This study investigates whether activating Mc1r with NDP-MSH could specifically counteract the oxidative stress and neuronal death that characterize SBI after ICH.
Study Design
Researchers induced an intracerebral hemorrhage (ICH) in mice via autologous blood injection. One hour after inducing the hemorrhage, mice received an intraperitoneal injection of NDP-MSH. To confirm the mechanism of action, specific groups also received Mc1r siRNA to inhibit receptor expression or the PI3K inhibitor LY294002 to block a key downstream signaling molecule. The primary endpoints, assessed at 24 hours post-ICH, were neurological deficits and brain water content. Researchers used ELISA, TUNEL staining, immunofluorescence, and Western blot analysis to measure oxidative stress, apoptosis, and protein expression.
Results
Following ICH, Mc1r expression was significantly elevated in neurons within the affected brain hemisphere. Treatment with NDP-MSH markedly improved neurological function and reduced brain water content at 24 hours. This functional recovery was associated with a significant decrease in oxidative stress and neuronal apoptosis. Mechanistically, NDP-MSH administration promoted the expression of Mc1r and increased the phosphorylation of key proteins in the PI3K/Akt/Nrf2 pathway.
This activation led to a beneficial shift in apoptotic markers: an increase in the anti-apoptotic protein
Bcl-2and a reduction in the pro-apoptotic protein cleavedcaspase-3. Conversely, blockingMc1rwith siRNA or inhibitingPI3Kwith LY294002 not only worsened neurological deficits and brain edema but also completely abolished the protective effects of NDP-MSH on the entire signaling cascade, confirming the pathway's critical role.
Key Findings
- NDP-MSH treatment significantly attenuated neurological deficits and brain water content 24 hours after ICH in mice.
- Mc1r was primarily expressed in neurons, and its levels significantly increased in the ipsilateral hemisphere after ICH.
- NDP-MSH administration promoted expression of Mc1r, p-PI3K, p-Akt, and p-Nrf2.
- The protective effects of NDP-MSH were abolished by co-administration of an Mc1r siRNA or a PI3K inhibitor (LY294002).
- NDP-MSH treatment led to an increase in the anti-apoptotic protein Bcl-2 and a reduction in cleaved caspase-3.
Why It Matters
This study highlights a specific, actionable pathway for mitigating the devastating secondary brain injury that follows a hemorrhagic stroke. For researchers and biohackers exploring neuroprotective compounds, it positions NDP-MSH (Melanotan I) as a potential agent for acute post-injury intervention, acting through the well-defined PI3K/Akt/Nrf2 pathway. The findings suggest that timing is critical, with administration 1 hour post-event showing efficacy. The primary takeaway is that NDP-MSH's neuroprotective benefit in this context is directly linked to MC1R activation and downstream signaling, offering a clear mechanism to target for post-stroke recovery protocols. This is preclinical animal data, so human translation requires extensive safety and efficacy trials to determine appropriate dosing, timing, and clinical relevance. It does, however, provide a strong rationale for investigating melanocortin agonists in acute neurological injury.
